Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Univariable GEE associations of global rating of change status with SLEQOL, SF36 surveys and clinical indicators

From: Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study

GRC statusOutcomes
HRQoL surveysSLE clinical indicators (present at visit)
SLEQOL (SLE-specific)SF36 (generic)In LLDASSLEDAI-2K > 4MM/S flareOrgan damage
PCSMCS
 Mean (95% CI)Mean (95% CI)Mean (95% CI)Freq. visits (%)Freq. visits (%)Freq. visits (%)Freq. visits (%)
No change (no. visits = 471)88.4 (87.2, 89.7)46.9 (46.1, 47.8)49.5 (48.6, 50.5)219 (46.6%)127 (27.0%)82 (17.4%)215 (45.6%)
Deterioration (no. visits = 250)79.6 (77.4, 81.7)42.8 (41.8, 43.8)47 (45.7, 48.2)82 (32.8%)97 (38.8%)66 (26.4%)157 (62.8%)
Improvement (no. visits = 1007)88.8 (87.7, 89.9)47.9 (47.2, 48.7)50.1 (49.2, 50.9)525 (52.2%)259 (25.7%)130 (12.9%)517 (51.3%)
 Mean diff. (95% CI), p valueMean diff. (95% CI), p valueMean diff. (95% CI), p valueOdds ratio (95% CI), p valueOdds ratio (95% CI), p valueOdds ratio (95% CI), p valueOdds ratio (95% CI), p value
No change (ref.)0001.001.001.001.00
Deterioration− 8.9 (−11.1, − 6.7), p < 0.01− 4.12 (− 5.2, − 3.1), p < 0.01− 2.53 (− 3.9, − 1.2), p < 0.010.59 (0.43, 0.80), p < 0.011.61 (1.18, 2.19), p < 0.011.83 (1.27, 2.64), p < 0.011.12 (1.01, 1.25), p = 0.04
Improvement0.4 (− 0.5, 1.3), p = 0.40.96 (0.3,1.6), p < 0.010.54 (− 0.2,1.3), p = 0.171.30 (1.07, 1.57), p = 0.010.85 (0.70, 1.04), p = 0.110.70 (0.52, 0.95), p = 0.021.01 (0.93, 1.10), p = 0.8
  1. Freq. visits = frequency of visits, Mean diff. = mean difference